NMPA to Launch Pre-Submission Consultation Services for Medical Device Clinical Trial Protocols in 2027
China’s National Medical Products Administration (NMPA) announced on November 11, 2026, that it will launch pre-submission consultation services for clinical trial protocols of Class III medical devices, including in vitro diagnostic (IVD) reagents, effective January 1, 2027.
Eligible products must have completed product design finalization and necessary non-clinical studies. Applicants for innovative medical devices already included in the Special Review Procedure may apply directly to the Center for Medical Device Evaluation (CMDE) through the existing pathway. For other domestic products, applications must first be submitted to the provincial drug regulatory authority for preliminary review before being forwarded to CMDE. Overseas applicants may submit applications through their domestic agents directly to CMDE.
Under this service, CMDE will review relevant issues concerning proposed clinical trial protocols and provide feedback to guide applicants in conducting clinical trials. Detailed implementation arrangements will be announced separately by CMDE.